Toxic effects of copper-based antineoplastic drugs (Casiopeinas®) on mitochondrial functions

Biochemical Pharmacology

Volumn 65, Issue 12, 2003, Pages 1979-1989

  Marín Hernández, Alvaro ^a   Gracia Mora, Isabel ^b   Ruiz Ramírez, Lena ^b   Moreno Sánchez, Rafael ^a,c  

^a INSTITUTO NACIONAL DE CARDIOLOGÍA IGNACIO CHÁVEZ   (Mexico)

^b UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

^c UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

Author keywords

2 Oxoglutarate dehydrogenase; Cytochrome c release; K+ channel openers; Membrane potential; O2 uptake; Swelling

Indexed keywords

(4,4 DIMETHYL 2,2 BIPYRIDINE)(ACETYLACETONATE)COPPER NITRATE; (4,7 DIMETHYL 1,10 PHENANTHROLINE)(GLYCINATE)COPPER NITRATE; ADENOSINE TRIPHOSPHATASE; ANTINEOPLASTIC AGENT; CASIOPEINAS; COPPER; CYTOCHROME C; HYDROGEN; METAL; OLIGOMYCIN; OXOGLUTARATE DEHYDROGENASE; POTASSIUM; SUCCINATE DEHYDROGENASE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BIOCHEMISTRY; CELL FUNCTION; CELL STRAIN; CELL SWELLING; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOTOXICITY; DRUG EXPOSURE; DRUG POTENCY; DRUG SENSITIVITY; INCUBATION TIME; INHIBITION KINETICS; KIDNEY; LIVER; LIVER CELL CARCINOMA; MEASUREMENT; MITOCHONDRIAL RESPIRATION; MITOCHONDRION; NONHUMAN; PRIORITY JOURNAL; RAT; REGULATORY MECHANISM;

EID: 0038730445     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(03)00212-0     Document Type: Article

References (62)

1. Rosencweig M., Von Hoff D.D., Slavik M., Muggia F.M. Cisdiamminedichloroplatinum(II). A new anticancer drug. Ann. Int. Med. 86:1977;803-812.
2. Williams S.D., Einhorn L.H. Cisplatinum in the treatment of testicular and other cancers. Adv. Int. Med. 27:1982;531-545.
3. Ensley J.F., Jacobs J.R., Weaver A., Kinzie J., Crissman J., Kish J.A., Cummings G., Al-Sarraf M. Correlation between response to cisplatinum-combination chemotherapy and subsequent radiotherapy in previously untreated patients with advanced squamous cell cancers of the head and neck. Cancer. 54:1984;811-814.
4. Dobyan D.C., Levi J., Jacobs C., Kosek J., Weiner M.W. Mechanism of cisplatinum nephrotoxicity. II. Morphologic observations. J. Pharmacol. Exp. Ther. 213:1980;551-556.
5. De Conti R.C., Toflness B.R., Lange R.C., Creasey W.A. Clinical and pharmacological studies with cisdiamminedichloroplatinum(II). Cancer Res. 33:1973;1310-1315.
6. Porter G.A., Bennett W.M. Nephrotoxic acute renal failure due to common drugs. Am. J. Physiol. 241:1981;F1-F8.
7. Goldstein R.S., Mayor G.H. The nephrotoxicity of cisplatin. Life Sci. 32:1983;685-690.
8. Gordon J.A., Gattone V.H. Mitochondrial alterations in cisplatin-induced acute renal failure. Am. J. Physiol. 250:1986;F991-F998.
9. Safirstein R., Miller P., Guttenplan J.B. Uptake and metabolism of cisplatin by rat kidney. Kidney Int. 25:1984;753-758.
10. Levi J., Jacobs S.M., Kalman M., McTigue M., Weiner M.W. Mechanism of cisplatinum nephrotoxicity. I. Effects of sulfhydryl groups in rat kidneys. J. Pharmacol. Exp. Ther. 213:1980;545-550.
11. Choie D.D., del Campo A.A., Guarino A.M. Subcellular localization of cisdichlorodiammineplatinum(II) in rat kidney and liver. Toxicol. Appl. Pharmacol. 55:1980;245-252.
12. Kruidering M., Van de Water B., de Heer E., Mulder G.J., Nagelkerke J.F. Cisplatin-induced nephrotoxicity in porcine proximal tubular cells: mitochondrial dysfunction by inhibition of complexes I to IV of the respiratory chain. J. Pharmacol. Exp. Ther. 280:1997;638-649.
13. Brady H.R., Kone B.C., Stromski M.E., Zeidel M.L., Giebish G., Gullans S.R. Mitochondrial injury: an early event in cisplatin toxicity to renal proximal tubules. Am. J. Physiol. 258:1990;F1181-F1187.
14. Melendez-Zajgla J., Cruz E., Maldonado V., Espinoza A.M. Mitochondrial changes during the apoptotic process of HeLa cells exposed to cisplatin. Biochem. Mol. Biol. Int. 47:1999;765-771.
15. Andrews P.A., Albright K.D. Mitochondrial defects in cisdiamminedichloroplatinum(II)-resistant human ovarian carcinoma cells. Cancer Res. 52:1992;1895-1901.
16. Kharbangar A., Khynriam D., Prasad S.B. Effect of cisplatin on mitochondrial protein, glutathione, and succinate dehydrogenase in Dalton lymphoma-bearing mice. Cell. Biol. Toxicol. 16:2000;363-373.
17. Kuhlmann M.K., Burkhardt G., Kohler H. Insights into potential cellular mechanisms of cisplatin nephrotoxicity and their clinical application. Nephrol. Dial Transplant. 12:1997;2478-2480.
18. Cavalli L.R., Liang B.C. Mutagenesis, tumorigenicity, and apoptosis: are the mitochondria involved? Mutat. Res. 398:1998;19-26.
19. Penta J.S., Johnson F.M., Wachsman J.T., Copeland W.C. Mitochondrial DNA in human malignancy. Mutat. Res. 488:2001;119-133.
20. Backer J.M., Weinstein I.B. Mitochondrial DNA is a major cellular target for a dihydrodiol-epoxide derivative of benzo[a]pyrene. Science. 209:1979;297-299.
21. Allen J.A., Coombs M.M. Covalent binding of polycyclic aromatic compounds to mitochondrial and nuclear DNA. Nature. 287:1980;244-245.
22. Niranjan B.G., Bhat N.K. Preferential attack of mitochondrial DNA by aflatoxin b, during hepatocarcinogenesis. Science. 215:1982;73-75.
23. Murata T., Hibasami H., Maekawa S., Tagawa T., Nakashima K. Preferential binding of cisplatin to mitochondrial dna and suppression of ATP generation in human malignant melanoma cells. Biochem. Int. 20:1990;949-955.
24. Olivero O.A., Semino C., Kassim A., López-Larraza D.M., Poirer M.C. Preferential binding of cisplatin to mitochondrial DNA of Chinese hamster ovary cells. Mutat. Res. 346:1995;221-230.
25. Lim L.O., Neims A.H. Mitochondrial DNA damage by bleomycin. Biochem. Pharmacol. 36:1987;2769-2774.
26. Clayton D.A., Doda J.N., Friedberg E.C. The absence of a pyrimidine dimer repair mechanism in mammalian mitochondria. Proc. Natl. Acad. Sci. U.S.A. 71:1974;2777-2781.
27. 2: evidence for mitochondrial involvement. Cancer Res. 54:1994;1497-1502.
28. Gracia-Mora I., Ruiz-Ramírez L., Gómez-Ruiz C., Tinoco-Méndez M., Márquez-Quiñones A., Romero de Lira L., Marín-Hernández A., Macías-Rosales L., Bravo-Gómez M.E. Knight's move in the periodic table, from copper to platinum, novel antitumor mixed chelate copper compounds, casiopeinas, evaluated by an in vitro human and murine cancer cell line panel. Metal Based Drugs. 8:2001;19-28.
29. De Vizcaya-Ruiz A., Rivero-Mueller A., Ruiz-Ramírez L., Kass G.E.N., Kelland L.R., Orr R.M., Dobrota M. Induction of apoptosis by a novel copper-based anticancer compound, casiopeina II, in L1210 murine leukaemia and CH1 human ovarian carcinoma cells. Toxicol In Vitro. 14:2000;1-5.
30. Ferrer-Sueta G., Ruiz-Ramírez L., Radi R. Ternary copper complexes and manganese(III) tetrakis (4-benzoic acid) porphyrin catalyze peroxynitrite-dependent nitration of aromatics. Chem. Res. Toxicol. 10:1997;1338-1344.
31. Arnaudeau C., Tenorio-Miranda E., Jenssen D., Helleday T. Inhibition of DNA synthesis is a potent mechanism by which cytostatic drugs induce homologous recombination in mammalian cells. Mutat. Res. 461:2000;221-228.
32. Ruíz Azuara L. US Patent Ap. 21 (1992) Number 5, 107, 005. US Patent Re 35, 458, Febeuary 18 (1997). US Patent November 19 (1996) Number 5, 576, 326. 407543 SECOFI; 1993.
33. 2+ concentrations. J. Biol. Chem. 260:1985;4028-4034.
34. Moreno-Sánchez R., Devars S., López-Gómez F., Uribe A., Corona N. Distribution of control of oxidative phosphorylation in mitochondria oxidizing NAD-linked substrates. Biochim. Biophys Acta. 1060:1991;284-292.
35. 2+ concentration. Biochem. J. 256:1988;403-412.
36. López-Gómez F., Torres-Márquez M.E., Moreno-Sánchez R. Control of oxidative phosphorylation in AS-30D hepatoma mitochondria. Int. J. Biochem. 25:1993;373-377.
37. Thayer W.S., Rubin E. Effects of chronic ethanol intoxication on oxidative phosphorylation in rat liver submitochondrial particles. J. Biol. Chem. 254:1979;7717-7723.
38. Weickowski M.R., Wojtczak L. Fatty acid-induced uncoupling of oxidative phosphorylation is partly due to opening of the mitochondrial permeability transition pore. FEBS Lett. 423:1998;339-342.
39. Moreno-Sánchez R., Bravo C., Vásquez C., Ayala G., Silveira L.H., Martínez-Lavín M. Inhibition and uncoupling of oxidative phosphorylation by nonsteroidal antiinflammatory drugs. Biochem. Pharmacol. 57:1999;743-752.
40. 1-ATPase. Eur. J. Biochem. 267:2000;993-1000.
41. 2+, and other effectors. Arch. Biochem. Biophys. 379:2000;78-84.
42. - stoichiometries at the individual coupling sites in mitochondrial oxidative phosphorylation. J. Biol. Chem. 262:1987;10445-10453.
43. Inomoto T., Tanaka A., Moris M.B., Sato B., Yanabu N., Tokuka A., Kitai T., Ozawa K., Yamaoka Y. Changes in the distribution of the control of the mitochondrial oxidative phosphorylation in regenerating rabbit liver. Biochim. Biophys. Acta. 1188:1994;311-317.
44. 2+ in pancreas and adrenal cortex mitochondria. Arch. Biochem. Biophys. 319:1995;432-444.
45. Singer T.P., Kearney E.B., Kenney W.C. Succinate dehydrogenase. Adv. Enzymol. 37:1973;189-271.
46. Chappell JB, Haarhoff KN. The penetration of the mitochondrial membrane by anions and cations. In: Slater EC, Kanuiga Z, Wojtczak L, editors. Biochemistry of mitochondria. London: Academic Press; 1967. p. 75-91.
47. Szewczyk A., Wojtczak L. Mitochondria as a pharmacological target. Pharmacol. Rev. 54:2002;101-127.
48. Wojtczak L., Nikitina E.R., Czyz A., Skulskii I.A. Cuprous ions activate glibenclamide-sensitive potassium channel in liver mitochondria. Biochem. Biophys. Res. Commun. 223:1996;468-473.
49. +-channels modulate cardiac mitochondrial function. Am. J. Physiol. 275:1998;H1567-H1576.
50. +-channel of heart mitochondria. Am. J. Physiol. 280:2001;H649-H657.
51. +-channel and its involvement in cytochrome c release. J. Bioeng. Biomembr. 34:2002;177-184.
52. L as an inhibitor of cytosolic cytocrome c accumulation in DNA damage-induced apoptosis. Proc. Natl. Acad. Sci. U.S.A. 94:1997;6939-6942.
53. Cai J., Yang J., Jones D.P. Mitochondrial control of apoptosis: the role of cytochrome c. Biochim. Biophys. Acta. 1366:1998;139-149.
54. Rosen M., Figlioimeni M., Simpkins H. The interaction of platinum antitumour drugs with mouse liver mitochodria. Int. J. Exp. Path. 73:1992;61-74.
55. Singh G. A possible cellular mechanism of cisplatin-induced nephrotoxicity. Toxicology. 58:1989;71-80.
56. Choie D.D., Longnecker D.S., del Campo A.A. Acute and chronic cisplatin nephrotoxicity in rats. Lab. Inv. 44:1981;397-402.
57. Summerhayes I.C., Lampidis T.J., Bernal S.D., Nadakavukaren J.J., Nadakavukaren K.K., Shepherd E.L., Chen L.B. Unusual retention of rhodamine 123 by mitochondria in muscle and carcinoma cells. Proc. Natl. Acad. Sci. U.S.A. 79:1982;5292-5296.
58. Nadakavukaren K.K., Nadakavukaren J.J., Chen L.B. Increased rhodamine 123 uptake by carcinoma cells. Cancer Res. 45:1985;6093-6099.
59. Koya K., Li Y., Wang H., Ukai T., Tatsuta N., Kawakami M., Shishido T., Chen L.B. MKT-077, a novel rhodacyanine dye in clinical trials, exhibits anticarcinoma activity in preclinical studies based on selective mitochondrial accumulation. Cancer Res. 56:1996;538-543.
60. Davis S., Weiss M.J., Wong J.R., Lampidis T.J., Chen L.B. Mitochondrial and plasma membrane potentials cause unusual accumulation and retention of rhodamine 123 by human breast adenocarcinoma-derived MCF-7 cells. J. Biol. Chem. 260:1985;13844-13850.
61. Weiss M.J., Wong J.R., Ha C.S., Bleday R., Salem R.R., Steele G.D., Chen L.B. Dequalinium, a topical antimicrobial agent, displays anticarcinoma activity based on selective mitochondrial accumulation. Proc. Natl. Acad. Sci. U.S.A. 84:1987;5444-5448.
62. Modica-Napolitano J., Aprille J.R. Basis for the selective cytotoxicity of rhodamine 123. Cancer Res. 47:1987;4361-4365.